Loading...
•
Dec 31, 2020
Chemours Q4 2020 Earnings Report
Chemours reported strong fourth quarter results with solid momentum across core markets.
Key Takeaways
Chemours Company reported fourth-quarter net sales of $1.3 billion, nearly level with the prior-year quarter. Net income was $19 million, resulting in EPS of $0.11. Adjusted EBITDA increased by 8% year-over-year to $246 million, driven by higher volume, lower costs, and favorable currency impact.
Net Sales of $1.3 billion, nearly level with prior-year quarter
Net Income of $19 million, with EPS of $0.11
Adjusted Net Income of $103 million, with Adjusted EPS of $0.61
Adjusted EBITDA of $246 million up 8% year-over-year
Chemours
Chemours
Forward Guidance
The company expects to deliver 2021 Adjusted EBITDA within a range of $1.0 to $1.15 billion. Capital expenditures are expected to be approximately $350 million, with Free Cash Flow of greater than $350 million. The company expects to deliver Adjusted EPS of between $2.40 and $3.12.
Positive Outlook
- Adjusted EBITDA between $1.0 to $1.15 billion, up 22% from 2020 at the mid-point
- Adjusted EPS between ~$2.40 and $3.12
- Capex of ~$350 million with Free Cash Flow expected to be greater than $350 million
- Since spin we have transformed the company to be more resilient
- We have invested behind key growth strategies.
Challenges Ahead
- Natural uncertainty in the progression of the global COVID-19 pandemic.
- The COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets
- Extreme volatility in financial and commodity markets
- A significant slowdown in economic activity
- Increased predictions of a global recession.